Cefotetan for E. coli Infections

JL
KL
Overseen ByKristina L. Bajema
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This pilot study will compare clinical outcomes among patients treated with cefotetan versus standard of care antibiotics for bacteremia or genitourinary infections caused by E. coli. It will also measure cefotetan minimum inhibitory concentration (MIC) distributions and cefotetan trough serum concentrations.

Are You a Good Fit for This Trial?

Inclusion Criteria

Identified within 48 hours of inpatient antibiotic administration for acute illness
Patient or legally authorized representative are able to provide informed consent for participation in the study
I have a blood infection caused by E. coli from a urinary source.
See 1 more

Exclusion Criteria

Allergy to cefotetan
Pregnant or breastfeeding
History of cephalosporin-associated hemolytic anemia
See 8 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants are randomized to receive either cefotetan or standard of care antibiotics for their infection

7 days
Daily monitoring (in-person)

Follow-up

Participants are monitored for clinical outcomes, including absence of death, recurrent E. coli bacteremia, or need for additional antibiotic treatment

30 days

What Are the Treatments Tested in This Trial?

Interventions

  • Cefotetan

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Active Control

Group I: CefotetanExperimental Treatment1 Intervention
Group II: Standard of care antibioticsActive Control2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Oregon Health and Science University

Lead Sponsor

Trials
1,024
Recruited
7,420,000+